XenoPort, Inc. (NASDAQ: XNPT) on 29 January announced the pricing of $100 million aggregate principal amount of 2.50% Convertible Senior Notes due 2022 in a private placement to qualified institutional buyers pursuant to Rule 144A (the “offering”) under the Securities Act of 1933, as amended (the “Securities Act”). In connection with the offering, XenoPort also granted the initial purchasers of the notes a 30-day option to purchase up to an additional $15 million aggregate principal amount of the notes to cover over-allotments, if any.On Tuesday shares of Xenoport, Inc. (NASDAQ:XNPT) closed at $7.36. Company’s sales growth for last 5 years was -28.20% and EPS growth for next 5 years is recorded as 5.00%.
Onconova Therapeutics, Inc. (NASDAQ:ONTX) announced that following discussions regarding the future development of rigosertib with the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and several European national regulatory agencies, the Company has solidified its plans for a Phase 3 clinical trial for rigosertib in HR-MDS patients after failure of treatment with HMAs. Onconova Therapeutics, Inc. (NASDAQ:ONTX) in last trading activity decreased -36.41% to close at $2.55. Company weekly performance is -29.56% while its quarterly performance stands at -47.53%. Onconova Therapeutics, Inc. (NASDAQ:ONTX) is -83.44% away from its 52 week high.
An investigation on behalf of investors of Advaxis, Inc. (NASDAQ:ADXS) shares over potential securities laws violations by Advaxis, Inc. and certain of its directors and officers in connection certain financial statements was announced on 26 January. On last trading day Advaxis, Inc. (NASDAQ:ADXS) decreased -8.96% to close at $8.74. Its volatility for the week is 13.95% while volatility for the month is 16.79%. ADXS’s EPS growth for past 5 years was -24.50%. Advaxis, Inc. (NASDAQ:ADXS) monthly performance is 3.80%.
On Thursday, January 23, 2015, Regado Biosciences, Inc., (NASDAQ:RGDO) a Delaware corporation Landmark Merger Sub, Inc., a Delaware corporation (“Merger Sub”), Tobira Therapeutics, Inc., a Delaware corporation (“Tobira”) and Brent Ahrens as the Company Stockholders’ Agent (the “Stockholders’ Agent”) entered into an amendment (the “Amendment”) to the Agreement and Plan of Merger and Reorganization dated as of January 14, 2015 between the Company, Merger Sub, Tobira and the Stockholders’ Agent (the “Merger Agreement”). Pursuant to the Merger Agreement, as amended by the Amendment, Merger Sub will be merged with and into Tobira (the “Merger”), with Tobira surviving the Merger as a wholly-owned subsidiary of the Company. Regado Biosciences, Inc. (NASDAQ:RGDO) has 9.60% insider ownership while its institutional ownership stands at 47.30%. In last trading activity company’s stock closed at $1.21.
Omeros Corporation (NASDAQ: OMER) announced that it has closed the underwritten public offering that was priced and allocated to investors on January 28, 2015 relating to the sale of 3,444,831 shares of its common stock at a price of $20.03 per share and 749,250 pre-funded warrants to purchase up to an equal number of shares of its common stock at a price per warrant of $20.02, which was paid at closing. On last trading day Omeros Corporation (NASDAQ:OMER) decreased -6.57% to close at $19.20. Its volatility for the week is 10.11% while volatility for the month is 6.41%. OMER’s sales growth for past 5 years was 5.90% and its EPS growth for past 5 years was 30.00%. Omeros Corporation (NASDAQ:OMER) monthly performance is -23.23%.